Cambridge biotech firm hampered by US indecisions
Cambridge biotech company Abam plc reported that funding uncertainties have created pressure for them.
Looking on the six months to the end of December, the firm said the postponement of a federal decision on research expenditure in the US was hampering revenue growth in one of its key markets.
Abam expect to report revenue growth of between 28%-30%. The integration of US biotech counterpart, Epitomics was said to be going well, with sales for the arm now being made through Abam’s platform.
The addition of Epitomics would increase gross margins over the period, and Abam plan to continue with “tight cost control” measures.
This was posted in Bdaily's Members' News section by Tom Keighley .